 |
|
Repetitive low-dose tissue plasminogen activator for the clearance of experimental vitreous hemorrhage.
Woog Ki Min, Yong Baek Kim, Byung Heon Ahn, Geun Hae Seong
Korean J Ophthalmol. 1994;8(2):45-48. Published online 1994 Dec 30 DOI: https://doi.org/10.3341/kjo.1994.8.2.45
|
|
Citations to this article as recorded by
 INTRAVITREAL TISSUE PLASMINOGEN ACTIVATOR, PERFLUOROPROPANE (C3F8), AND RANIBIZUMAB OR PHOTODYNAMIC THERAPY FOR SUBMACULAR HEMORRHAGE SECONDARY TO WET AGE-RELATED MACULAR DEGENERATION
Evangelia Papavasileiou, David H. W. Steel, Efstathios Liazos, Dominic McHugh, Timothy L. Jackson
Retina.2013; 33(4): 846. CrossRef A Vitreous Hemorrhage Animal Model in Rabbits Using Force Percussion Injury
Hua Yan, Arslan Saeed Ahmed, Jindong Han, Jing Cui, Jinguo Yu
Current Eye Research.2009; 34(9): 717. CrossRef Vitreous Haemorrhage in Elderly Patients
Kaykhosrov Manuchehri, Graham R Kirkby
Drugs & Aging.2003; 20(9): 655. CrossRef Tissue Plasminogen Activator in the Treatment of Vitreoretinal Diseases
Motohiro Kamei, Marc Estafanous, Hilel Lewis
Seminars in Ophthalmology.2000; 15(1): 44. CrossRef Vitreous hemorrhage
Christoph W. Spraul, Hans E. Grossniklaus
Survey of Ophthalmology.1997; 42(1): 3. CrossRef
|